Drugs / MEN1112
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02353143 | Dec 2014 → Apr 2021 | acute myeloid leukemia | Menarini Group | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-09-19 | Menarini Group | Results Menarini Ricerche Announces New Positive Results in Acute Myeloid Leukemia Cell Lines for MEN1112/OBT357 at the 60th Annual SIC Meeting menarini.com ↗
The experimental results that will be presented strongly suggest that pre-treatment with 5-Azacytidine and Decitabine enhances the cell killing activity of MEN1112/OBT357 on SKNO-1, HL60 and K052 cell lines. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-09-19 | Menarini Group | Menarini Ricerche Announces New Positive Results in Acute Myeloid Leukemia Cell Lines for MEN1112/OBT357 at the 60th Annual SIC Meeting menarini.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEN1112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02353143 ↗ |
| Modality | Monoclonal antibody | “a CD157 Targeted Monoclonal Antibody” NCT02353143 ↗ |
| Route | Intravenous | “given as intravenous infusion” NCT02353143 ↗ |